ClinicalTrials.gov
ClinicalTrials.gov Menu

Reducing High Risk Behavior in Treatment Court

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01481428
Recruitment Status : Completed
First Posted : November 29, 2011
Last Update Posted : January 10, 2017
Sponsor:
Collaborator:
National Institute on Drug Abuse (NIDA)
Information provided by (Responsible Party):
Treatment Research Institute

Study Description
Go to 
Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
This study will be the first to examine the efficacy of using a brief, computerized HIV risk reduction intervention in treatment courts.

Condition or disease Intervention/treatment Phase
Substance Abuse HIV Behavioral: Computer-facilitated HIV intervention Behavioral: Attention Control Phase 1

Detailed Description:
Four hundred consenting treatment drug court participants will be randomly assigned to either an HIV intervention group (n = 200) or an attention control group. All clients will attend their regularly scheduled status hearings which are scheduled approximately every six weeks. Clients in the HIV intervention group will receive a brief computerized, self-administered HIV risk reduction intervention following each of their first three status hearings. Clients in the attention control condition will view a series of educational life-skill videos of matched length following each of their first three status hearings. The primary outcome will be engagement in high risk behaviors as measured by the Risk Assessment Battery (RAB). Secondary HIV-related outcomes will include: (1) rate of HIV testing, (2) condom procurement, and (3) self-reported condom use. Tertiary outcomes related to treatment court compliance will include: (1) drug court graduation, (2) urinalysis-confirmed drug abstinence, (3) case management attendance, and (4) satisfaction with case management. In addition, we will conduct preliminary cost and cost-effectiveness analyses on the delivery of the brief computerized HIV intervention. Assessments will be conducted at baseline and 9- and 15-months post admission.

Study Design
Go to 
Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 371 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Prevention
Official Title: Delivering HIV Risk Reduction Services in Treatment Court
Study Start Date : September 2012
Actual Primary Completion Date : December 2016
Actual Study Completion Date : December 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS
U.S. FDA Resources

Arms and Interventions
Go to 
Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Active Comparator: Attention Control Behavioral: Attention Control
Life skills training DVDs that match the duration of the anticipated experimental condition. The DVDs address topics such as positive listening skills, anger management, and stress reduction.
Experimental: Computer-facilitated HIV intervention Behavioral: Computer-facilitated HIV intervention
Individuals assigned to the experimental condition will complete the self-directed CARE HIV intervention during each of their first three sessions. The 20 minute intervention sessions involve several components including a brief risk assessment, review of identified risks, structured skill building videos, and the development of a risk prevention action plan. Because of the adaptive nature of the CARE program, the content of each session will be tailored to address the current risks of the participant. While the main focus of the intervention is on risk, individuals who report being HIV infected will receive a referral to treatment if they are not currently receiving medical care and their session will address, among other things, adherence to HIV care.


Outcome Measures
Go to 
Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Engagement in high risk behaviors [ Time Frame: 15 month follow-up ]
    Measured by the Risk Assessment Battery (RAB)


Secondary Outcome Measures :
  1. Rate of HIV testing [ Time Frame: 15 month follow-up ]
  2. Condom Procurement [ Time Frame: 15 month follow-up ]
  3. Self-reported Condom Use [ Time Frame: 15 month follow-up ]

Eligibility Criteria
Go to 
Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. be at least 18 years of age;
  2. be charged with a non-violent felony offense
  3. have no more than two prior non-violent convictions or diversionary opportunities
  4. be willing to participate in the treatment court program for at least 12 months
  5. be in need of treatment for substance abuse or dependence as assessed by case management.

Exclusion Criteria:

  • Elderly subjects and those with medical problems will be included in the research as long as they do not have any physical or psychiatric condition that would impede their ability to give competent consent to research participation or to understand the research instruments.
  • Those individuals who are intoxicated, cognitively impaired, or psychiatrically unstable when approached will not be included; however, such individuals may subsequently be included if the disqualifying condition subsides.
  • Spanish speaking only individuals.
  • Client remanded to jail or residential treatment facilities at the time of Treatment Court enrollment.
Contacts and Locations
Go to 
Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01481428


Locations
United States, Pennsylvania
Philadelphia Treatment Court
Philadelphia, Pennsylvania, United States, 19107
Sponsors and Collaborators
Treatment Research Institute
National Institute on Drug Abuse (NIDA)
Investigators
Principal Investigator: David S Festinger, Ph.D. Treatment Research Institute
More Information
Go to 
Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Responsible Party: Treatment Research Institute
ClinicalTrials.gov Identifier: NCT01481428     History of Changes
Other Study ID Numbers: #1002
R01DA030257 ( U.S. NIH Grant/Contract )
First Posted: November 29, 2011    Key Record Dates
Last Update Posted: January 10, 2017
Last Verified: January 2017

Keywords provided by Treatment Research Institute:
High risk behavior
Drug court clients
Substance abuse
HIV intervention
Treatment Court Clients

Additional relevant MeSH terms:
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders